Press release
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics
Metastatic Prostate Cancer Pipeline Insight
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix
Multiple Myeloma Pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Myeloma treatment therapies, analyzes DelveInsight.
Multiple Myeloma Overview:
Multiple myeloma (MM) is a cancer characterized by the unchecked growth of abnormal plasma cells, which leads to the overproduction of monoclonal immunoglobulins. Without treatment, this condition can cause serious organ damage, commonly manifesting as high blood calcium levels, impaired kidney function, anemia, or bone pain due to lytic lesions.
The disease can present differently from person to person, with variations in symptoms, age at onset, and progression speed. While some individuals may not exhibit symptoms initially, others may experience severe health issues. The most frequently reported symptom is bone pain, especially in the lower back or ribs. Elevated calcium levels in the blood, known as hypercalcemia, can also be a significant sign of the disease.
Request for a detailed insights report on Multiple Myeloma pipeline insights [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Multiple Myeloma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple Myeloma Therapeutics Market.
Key Takeaways from the Multiple Myeloma Pipeline Report
*
DelveInsight's Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
*
In January 2025, Sanofi announced the results of its Phase III IRAKLIA trial evaluating Sarclisa (isatuximab) for multiple myeloma (MM). Conducted across 252 global sites, the trial involved 531 adult patients who had received at least one prior therapy, including lenalidomide and a proteasome inhibitor. The trial met its co-primary endpoints when Sarclisa was administered subcutaneously via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone (Pd).
*
In September 2025, Johnson & Johnson released findings from the Phase III CARTITUDE-4 trial, demonstrating that its cell therapy, CARVYKTI (ciltacabtagene autoleucel), significantly improved overall survival in multiple myeloma patients. The trial compared CARVYKTI to standard regimens such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) in patients previously treated with at least one therapy, including a proteasome inhibitor.
*
In August 2025, Swiss biopharmaceutical company Opna Bio initiated a Phase I trial for OPN-6602, an EP300/CBP bromodomain inhibitor for multiple myeloma. The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan, with plans to enroll up to 130 participants with relapsed or refractory MM at multiple U.S. sites.
*
In April 2025, Bristol Myers Squibb and 2seventy bio announced the FDA's approval of Abecma Registered (idecabtagene vicleucel; ide-cel) for adults with relapsed or refractory multiple myeloma after at least two prior therapies. These must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. Based on the KarMMa-3 trial, this expanded approval allows earlier use for triple-class exposed patients. Abecma is administered as a single infusion, with a recommended dose range of 300 to 510 x 10 CAR-positive T cells.
*
Key Multiple Myeloma companies such as CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others are evaluating new drugs for Multiple Myeloma to improve the treatment landscape.
*
Promising Multiple Myeloma pipeline therapies in various stages of development include Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, and others.
Multiple Myeloma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Multiple Myeloma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple Myeloma market.
Download our free sample page report on Multiple Myeloma pipeline insights [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Multiple Myeloma Emerging Drugs
*
Zevorcabtagene Autoleucel: Carsgen Therapeutics
*
Descartes 08: Cartesian Therapeutics
*
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
*
CID-103: CASI Pharmaceuticals
*
STI-1492: Sorrento Therapeutics
Multiple Myeloma Companies
Approximately 75 prominent companies are currently engaged in developing treatments for multiple myeloma. Of these, Carsgen Therapeutics has the most advanced drug candidate, which has reached the Registered stage.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Multiple Myeloma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple Myeloma Therapies and Key Companies: Multiple Myeloma Clinical Trials and advancements [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Multiple Myeloma Pipeline Therapeutic Assessment
- Multiple Myeloma Assessment by Product Type
- Multiple Myeloma By Stage
- Multiple Myeloma Assessment by Route of Administration
- Multiple Myeloma Assessment by Molecule Type
Download Multiple Myeloma Sample report to know in detail about the Multiple Myeloma treatment market @ Multiple Myeloma Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Multiple Myeloma Current Treatment Patterns
4. Multiple Myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple Myeloma Late-Stage Products (Phase-III)
7. Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple Myeloma Discontinued Products
13. Multiple Myeloma Product Profiles
14. Multiple Myeloma Key Companies
15. Multiple Myeloma Key Products
16. Dormant and Discontinued Products
17. Multiple Myeloma Unmet Needs
18. Multiple Myeloma Future Perspectives
19. Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Multiple Myeloma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-myeloma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-casi-pharmaceuticals-carsgen-therapeutics-cartesian-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics here
News-ID: 4115017 • Views: …
More Releases from ABNewswire
Artallin Redefines Original Hand-Painted Oil Paintings Online: The Best Alternat …
NEW YORK - Feb. 26, 2026 - For homeowners and interior designers searching for original hand-painted oil paintings online, the market has long been dominated by mass-produced prints or inaccessible gallery prices. Today, Artallin officially launches its new Direct-to-Consumer (DTC) platform in the United States, offering a trusted space to buy art directly from independent artists. Positioned as the ultimate real oil painting on canvas, not print solution, Artallin [https://artallin.com/]…
The Veekys RGBIC Frunk Light Pro is the First Must-Have Mod for the Tesla Model …
As the refreshed 2025 Tesla Model Y (project "Juniper") hits the streets, early adopters are already hunting for ways to personalize their new rides. While Tesla has undoubtedly refined the vehicle's interior aesthetics, one glaring omission remains: the front trunk (frunk) is still notoriously dark at night.
Enter Veekys [https://veekys.com/], a premium EV accessory brand that has quickly become a favorite among Tesla enthusiasts. Their latest release-the Frunk Light Pro for…
Pest Brothers, Inc. Shares Top Pest Prevention Tips for Homestead, FL Homes
Pest Brothers, Inc. offers practical tips to help prevent pests in Homestead, FL. From sealing entry points to proper waste management, these proactive strategies help homeowners protect their homes from common infestations and avoid costly damage.
Homestead, FL - Homeowners prepare for the warmer months, and the company offers expert advice to help prevent issues from invading homes. With years of experience in pest control, lawn care, and termite management, they…
Terminator Pest Control Helps Cambria Homeowners Identify Early Signs of Pest In …
Terminator Pest Control educates Cambria homeowners on recognizing the first signs of pest infestations. By acting early, they help prevent serious damage and reduce long-term pest control costs. Their expert team provides advice and tailored solutions for each unique situation.
Cambria, WI - Terminator Pest Control, a family-owned and trusted provider of management services, is helping homeowners identify early signs of infestations and take proactive steps to prevent costly damage. With…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
